Sarepta Therapeutics, Inc.
NEWS
History shows just how slow public health officials, the federal government, regulators and pharmaceutical companies were to respond to the emergence of HIV in the 1980s. The reasons are numerous—it was a puzzling viral disease, it first appeared in what was then a largely stigmatized patient population, gay men, and there weren’t really any existing treatments for viral diseases.
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne --
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
AcelRx is seeking $40 million to support the launch of Dsuvia and Sarepta eyes $500 million to support clinical research.
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
The American University Washington College of Law and the Food and Drug Law Institute hosted a conference late last week. One of the highlights was a plenary session that featured former commissioners of the U.S. Food and Drug Administration (FDA).
Sarepta Therapeutics’ experimental gene-therapy treatment for Duchenne muscular dystrophy (DMD) is showing some early signs of promise. Patients who received the therapy are showing increasing signs of a muscle protein that had been missing, the company said.
JOBS
IN THE PRESS